STOCK TITAN

[6-K] Haleon plc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Haleon plc announced the purchase of 5,150,000 ordinary shares of £0.01 each on 23 September 2025 as part of the second tranche of its share buyback programme. The company intends to hold the purchased shares as treasury shares.

After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 33,337,545 are treasury shares, leaving 8,919,016,103 ordinary shares with voting rights. The announcement includes a link to a full breakdown of individual trades and clarifies it is not an offer for securities.

Haleon plc ha annunciato l'acquisto di 5,150,000 azioni ordinarie da £0,01 ciascuna il 23 settembre 2025 nell'ambito della seconda tranche del proprio programma di riacquisto azioni. L'azienda intende detenere le azioni acquisite come azioni proprie.

Dopo la liquidazione, il capitale sociale registrato è 8,952,353,648 azioni ordinarie, di cui 33,337,545 sono azioni proprie, lasciando 8,919,016,103 azioni ordinarie con diritto di voto. L'annuncio include un link a una ripartizione completa delle singole operazioni e chiarisce che non si tratta di un'offerta di titoli.

Haleon plc anunció la compra de 5,150,000 acciones ordinarias de £0.01 cada una el 23 de septiembre de 2025 como parte de la segunda tramo de su programa de recompra de acciones. La empresa tiene la intención de mantener las acciones adquiridas como acciones en tesorería.

Después de la liquidación, el capital social registrado es de 8,952,353,648 acciones ordinarias, de las cuales 33,337,545 son acciones en tesorería, quedando 8,919,016,103 acciones ordinarias con derecho a voto. El anuncio incluye un enlace a un desglose completo de operaciones individuales y aclara que no es una oferta de valores.

Haleon plc는 2025년 9월 23일 주당 0.01파운드인 보통주 5,150,000주를 자사주 매입 프로그램의 두 번째 트랜치의 일부로 매입했다고 발표했습니다. 회사는 매입한 주식을 보유주로 보유할 의도가 있습니다.

정산 후 등록된 자본은 보통주 8,952,353,648주로, 그 중 33,337,545주가 보유주로, 유효의 의결권이 있는 보통주 수는 8,919,016,103주입니다. 공고에는 개별 거래의 전체 분석에 대한 링크가 포함되어 있으며 증권의 제안은 아님을 명확히 합니다.

Haleon plc a annoncé l'achat de 5 150 000 actions ordinaires de 0,01 £ chacune le 23 septembre 2025 dans le cadre de la deuxième tranche de son programme de rachat d'actions. L'entreprise a l'intention de conserver les actions achetées comme des actions propres.

Après le règlement, le capital social enregistré est de 8 952 353 648 actions ordinaires, dont 33 337 545 sont des actions propres, laissant 8 919 016 103 actions ordinaires avec droit de vote. L'annonce comprend un lien vers une ventilation complète des transactions individuelles et précise qu'il ne s'agit pas d'une offre de titres.

Haleon plc gab den Kauf von 5.150.000 Stammaktien zu je 0,01 £ am 23. September 2025 bekannt, im Rahmen der zweiten Tranche ihres Aktienrückkaufprogramms. Das Unternehmen beabsichtigt, die erworbenen Aktien als Treasury-Aktien zu halten.

Nach der Abwicklung beträgt das registrierte Grundkapital 8.952.353.648 Stammaktien, davon 33.337.545 als Treasury-Aktien, verbleiben 8.919.016.103 stimmberechtigte Stammaktien. Die Ankündigung enthält einen Link zu einer vollständigen Aufschlüsselung der einzelnen Trades und stellt klar, dass es sich nicht um ein Angebot von Wertpapieren handelt.

Haleon plc أعلنت عن شراء 5,150,000 سهمًا عاديًا بقيمة 0.01 جنيه إسترليني للسهم الواحد في 23 سبتمبر 2025 كجزء من الشريحة الثانية من برنامج إعادة شراء الأسهم لديها. تعتزم الشركة الاحتفاظ بالأسهم التي تم شراؤها كأسهم خزينة.

بعد التسوية، رأس المال المسجل للسهم هو 8,952,353,648 سهمًا عاديًا، من بينها 33,337,545 سهمًا خزينة، مما يترك 8,919,016,103 سهمًا عاديًا لها حقوق تصويت. يحتوي الإعلان على رابط لتقسيم كامل للصفقات الفردية ويؤكد أنه ليس عرضًا للأوراق المالية.

Haleon plc 在 2025 年 9 月 23 日宣布购买 5,150,000 股面值 0.01 英镑的普通股,作为其股票回购计划的第二阶段的一部分。公司拟将所购股份作为库藏股持有。

结算后,注册资本为 8,952,353,648 股普通股,其中 33,337,545 股为库藏股,剩余 8,919,016,103 股具有表决权。公告包含指向个人交易的完整分解的链接,并澄清这不是证券的要约。

Positive
  • Executed buyback of 5,150,000 shares under the announced programme, demonstrating active capital return measures
Negative
  • None.

Insights

TL;DR Share buyback executed; size is small relative to total shares, suggesting limited immediate EPS or voting impact.

The Company executed a tranche purchase of 5,150,000 shares and will hold them as treasury stock. Relative to registered share capital of 8,952,353,648 shares, this tranche represents roughly 0.06% of issued capital, indicating a modest capital reduction in this tranche. The action signals continued use of the announced buyback program but, given the tranche size versus outstanding shares, the near-term financial impact on per-share metrics is likely limited. Disclosure of individual trade details follows Market Abuse Regulation requirements.

TL;DR Treasury purchase aligns with announced buyback and maintains shareholder notification transparency.

Haleon confirmed purchased shares will be held as treasury shares and provided voting-rights headcount for regulatory transparency. The firm supplied a link to a full trade breakdown, meeting disclosure obligations. Holding shares in treasury can provide flexibility for future capital management or employee compensation plans without immediately cancelling issued capital. No governance changes or executive actions are disclosed in this filing.

Haleon plc ha annunciato l'acquisto di 5,150,000 azioni ordinarie da £0,01 ciascuna il 23 settembre 2025 nell'ambito della seconda tranche del proprio programma di riacquisto azioni. L'azienda intende detenere le azioni acquisite come azioni proprie.

Dopo la liquidazione, il capitale sociale registrato è 8,952,353,648 azioni ordinarie, di cui 33,337,545 sono azioni proprie, lasciando 8,919,016,103 azioni ordinarie con diritto di voto. L'annuncio include un link a una ripartizione completa delle singole operazioni e chiarisce che non si tratta di un'offerta di titoli.

Haleon plc anunció la compra de 5,150,000 acciones ordinarias de £0.01 cada una el 23 de septiembre de 2025 como parte de la segunda tramo de su programa de recompra de acciones. La empresa tiene la intención de mantener las acciones adquiridas como acciones en tesorería.

Después de la liquidación, el capital social registrado es de 8,952,353,648 acciones ordinarias, de las cuales 33,337,545 son acciones en tesorería, quedando 8,919,016,103 acciones ordinarias con derecho a voto. El anuncio incluye un enlace a un desglose completo de operaciones individuales y aclara que no es una oferta de valores.

Haleon plc는 2025년 9월 23일 주당 0.01파운드인 보통주 5,150,000주를 자사주 매입 프로그램의 두 번째 트랜치의 일부로 매입했다고 발표했습니다. 회사는 매입한 주식을 보유주로 보유할 의도가 있습니다.

정산 후 등록된 자본은 보통주 8,952,353,648주로, 그 중 33,337,545주가 보유주로, 유효의 의결권이 있는 보통주 수는 8,919,016,103주입니다. 공고에는 개별 거래의 전체 분석에 대한 링크가 포함되어 있으며 증권의 제안은 아님을 명확히 합니다.

Haleon plc a annoncé l'achat de 5 150 000 actions ordinaires de 0,01 £ chacune le 23 septembre 2025 dans le cadre de la deuxième tranche de son programme de rachat d'actions. L'entreprise a l'intention de conserver les actions achetées comme des actions propres.

Après le règlement, le capital social enregistré est de 8 952 353 648 actions ordinaires, dont 33 337 545 sont des actions propres, laissant 8 919 016 103 actions ordinaires avec droit de vote. L'annonce comprend un lien vers une ventilation complète des transactions individuelles et précise qu'il ne s'agit pas d'une offre de titres.

Haleon plc gab den Kauf von 5.150.000 Stammaktien zu je 0,01 £ am 23. September 2025 bekannt, im Rahmen der zweiten Tranche ihres Aktienrückkaufprogramms. Das Unternehmen beabsichtigt, die erworbenen Aktien als Treasury-Aktien zu halten.

Nach der Abwicklung beträgt das registrierte Grundkapital 8.952.353.648 Stammaktien, davon 33.337.545 als Treasury-Aktien, verbleiben 8.919.016.103 stimmberechtigte Stammaktien. Die Ankündigung enthält einen Link zu einer vollständigen Aufschlüsselung der einzelnen Trades und stellt klar, dass es sich nicht um ein Angebot von Wertpapieren handelt.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
24 September 2025 - “Transaction in Own Shares”
 
 
99.1
 
 
 
Haleon plc: Transaction in own shares
 
24 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,150,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Date of purchase:
23 September 2025
23 September 2025
23 September 2025
Number of Shares purchased:
3,950,000
1,200,000
-
Highest price paid per Share (p):
333.3000
333.3000
-
Lowest price paid per Share (p):
329.8000
330.0000
-
Volume weighted average price paid per Share (p):
331.6889
331.6687
-
 
The Company intends to hold the purchased shares as treasury shares.
 
Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 33,337,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,919,016,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/5197A_1-2025-9-23.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: September 24, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

FAQ

What did Haleon (HLNCF) announce in the 6-K filing?

Haleon announced the purchase of 5,150,000 ordinary shares on 23 September 2025 under the second tranche of its share buyback programme.

How many shares will Haleon hold as treasury after this transaction?

Following settlement, Haleon will hold 33,337,545 shares as treasury shares.

What is the number of ordinary shares with voting rights after the purchase?

The filing states there are 8,919,016,103 ordinary shares with voting rights after settlement.

Where can I find the full breakdown of individual trades for the buyback?

A full breakdown is available at the provided London Stock Exchange PDF link: http://www.rns-pdf.londonstockexchange.com/rns/5197A_1-2025-9-23.pdf and on Haleon's investor website.

Does this announcement constitute an offer for securities?

No. The filing explicitly states the announcement does not constitute an offer or solicitation for securities in any jurisdiction.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

39.31B
4.47B
0.02%
12.85%
0.36%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge